1. KDIGO (2009) Kidney disease: improving global outcomes CKD-MBD work group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 113:s1–s130
2. Schaefer B, Schlosser K, Wuhl E, Schall P, Klaus G, Schaefer F, Schmitt CP (2010) Long-term control of parathyroid hormone and calcium-phosphate metabolism after parathyroidectomy in children with chronic kidney disease. Nephrol Dial Transplant 25:2590–2595
3. Moe SM, Drueke TB, Block GA, Cannata-Andía JB, Elder GJ, Fukagawa M, Jorgetti V, Ketteler M, Lagman CB, Levin A, Macleod M, McCann L, McCulough PA, Ott SM, Wang AY, Weisinger JR, Wheeler DC (2009) KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int 76(suppl 113):S1–S130
4. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, Andress DL (2007) Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 71:31–38
5. Hansen D, Brandi L, Rasmussen K (2009) Treatment of secondary hyperparathyroidism in hemodialysis patients: a randomized clinical trial comparing paricalcitol and alfacalcidol. BMC Nephrol 10:28